Sharps Technology (NASDAQ:STSS) and Baxter International (NYSE:BAX) Head-To-Head Analysis

Sharps Technology (NASDAQ:STSS) and Baxter International (NYSE:BAX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Volatility and Risk

Sharps Technology has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Valuation and Earnings

This table compares Sharps Technology and Baxter International”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	N/A	N/A	-$9.84 million	($0.60)	-0.26
Baxter International	$15.00 billion	1.21	$2.66 billion	$5.20	6.87

Baxter International has higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sharps Technology and Baxter International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-100.69%	-71.53%
Baxter International	16.51%	18.06%	5.21%

Analyst Ratings

This is a breakdown of current ratings and price targets for Sharps Technology and Baxter International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	0	0	0	0	N/A
Baxter International	1	8	2	0	2.09

Baxter International has a consensus price target of $42.00, suggesting a potential upside of 16.76%. Given Baxter International’s higher possible upside, analysts clearly believe Baxter International is more favorable than Sharps Technology.

Institutional and Insider Ownership

17.2% of Sharps Technology shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 12.6% of Sharps Technology shares are owned by company insiders. Comparatively, 0.2% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Baxter International beats Sharps Technology on 10 of the 12 factors compared between the two stocks.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

About Baxter International

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company’s products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.